Methods of treating residual breast cancer with trastuzumab emtansine
MYPI2025000495A0Undetermined Publication Date: 2020-04-15GENENTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025000495
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-15
- Filing Date
- 2019-04-24
- Publication Date
- 2020-04-15
Abstract
Methods of treating patients having HER2-positive early breast cancer with the antibody-drug conjugate trastuzumab emtansine (T-DM1) are provided. Fig. 1
Need to check novelty before this filing date? Find Prior Art
